<DOC>
	<DOCNO>NCT01827852</DOCNO>
	<brief_summary>This prospective observational study evaluate efficacy safety first-line Avastin ( bevacizumab ) combination platinum-based chemotherapy different age group ( &lt; 60 , 60-69 , 70-79 , &gt; 80 year ) patient inoperable advanced , metastatic recurrent adenocarcinoma non-small cell lung cancer . Patients follow 18 month start first-line therapy .</brief_summary>
	<brief_title>AVAdeno Study : An Observational Study First-Line Avastin ( Bevacizumab ) Patients With Adenocarcinoma Lung</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically confirm inoperable advanced , metastatic recurrent predominantly nonsquamous adenocarcinoma nonsmall cell lung cancer Contraindications Avastin treatment accord Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>